Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis

To report outcome (freedom from local progression [FFLP], overall survival [OS] and toxicity) after stereotactic, palliative or highly conformal fractionated (>12) radiotherapy (SBRT, Pall-RT, 3DCRT/IMRT) for adrenal metastases in a retrospective multicenter cohort within the framework of German Society Radiation Oncology (DEGRO). Adrenal treated with SBRT (≤12 fractions, biologically effective dose [BED10] ≥ 50 Gy), 3DCRT/IMRT (>12 BED10 Gy) Pall-RT (BED10 < were eligible this analysis. In addition to unadjusted FFLP (Kaplan-Meier/log-rank), we calculated competing-risk-adjusted recurrence rate (CRA-LRR). Three hundred twenty-six patients 366 included by 21 centers (median follow-up: 11.7 months). Treatment was SBRT, 260, 27 79 cases, respectively. Most frequent primary tumors non-small-cell lung cancer (NSCLC; 52.5%), SCLC (16.3%) melanoma (6.7%). Unadjusted higher vs (P = .026) while numerical differences CRA-LRR between groups did not reach statistical significance (1-year CRA-LRR: 13.8%, 17.4% 27.7%). OS longer other .05) increased locally controlled landmark analysis .0001). Toxicity mostly mild; notably, four cases insufficiency occurred, two which likely caused immunotherapy tumor progression. Radiotherapy associated mild toxicity profile all favorable 1-year 3DCRT/IMRT. One-year OS. Dose-response analyses dataset are underway.